Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina

被引:50
|
作者
Uruena, Analia
Pippo, Tomas
Sol Betelu, Maria
Virgilio, Federico
Giglio, Norberto [1 ]
Gentile, Angela
Garcia Jimenez, Salvador [2 ]
Jauregui, Barbara [3 ]
Clark, Andrew D. [4 ]
Diosque, Maximo
Vizzotti, Carla
机构
[1] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina
[2] Org Panamer Salud, Buenos Aires, DF, Argentina
[3] Pan Amer Hlth Org, Washington, DC USA
[4] London Sch Hyg & Trop Med, London WC1, England
关键词
Pneumococcal conjugate vaccine; Cost effectiveness; Argentina; NONTYPABLE HAEMOPHILUS-INFLUENZAE; PROTEIN-D; PHID-CV; OTITIS-MEDIA; VACCINATION; CHILDREN; DISEASE; IMMUNOGENICITY; SAFETY;
D O I
10.1016/j.vaccine.2011.04.111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Since the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) were recently licensed for use in Argentina, both vaccines were evaluated to estimate the costs, health benefits and cost-effectiveness of adding a PCV to the routine child immunization schedule. Methodology: The integrated TRIVAC vaccine cost-effectiveness model from Pan American Health Organization's ProVac Initiative (Version 1.0.65) was used to assess the health outcomes of 20 successive cohorts from birth to 5 years of age. PCV-10 and PCV-13 were each compared to a scenario assuming no PCV vaccination. A 3 + 1 (three doses + booster) schedule and a vaccination price of US$ 20.75 per dose was assumed in the base case for both vaccines. Results: Introduction of PCV-13 rather than PCV-10 would increase the number of life years gained (LYG) by at least 10%. The number of LYG (and LYG after adjustment for DALY morbidity weights) was 56,882 (64,252) for PCV-10 compared to 65,038 (71,628) for PCV-13. From the health system perspective, the cost per DALY averted was US$ 8973 and US$ 10,948 for PCV-10 and PCV-13 respectively, and US$ 8546 and US$ 10,510 respectively, after incorporating costs saved by households. When PCV13 was compared to PCV10 directly, the additional benefits of PCV-13 was conferred at a cost of US$ 28,147 per DALY averted. Cost-effectiveness was influenced mainly by vaccine price, serotype replacement, pneumonia mortality and discount rate. Conclusion: Routine vaccination against S. pneumoniae in Argentina would be cost-effective with either PCV-10 or PCV-13. PCV-13, with higher coverage of local serotypes, would prevent more cases of pneumonia, invasive pneumococcal disease, sequelae and deaths with a higher number of LYG and DALYs averted, but PCV-10, due its higher impact in the prevention of AOM, would save more costs to the healthcare system. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4963 / 4972
页数:10
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of 10-and 13-valent pneumococcal conjugate vaccines in Peru
    Mezones-Holguin, Edward
    Canelo-Aybar, Carlos
    Clark, Andrew David
    Janusz, Cara Bess
    Jauregui, Barbara
    Escobedo-Palza, Seimer
    Hernandez, Adrian V.
    Vega-Porras, Denhiking
    Gonzalez, Marco
    Fiestas, Fabian
    Toledo, Washington
    Michel, Fabiana
    Suarez, Victor J.
    [J]. VACCINE, 2015, 33 : A154 - A166
  • [2] Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines
    Chuck, Anderson W.
    Jacobs, Philip
    Tyrrell, Gregory
    Kellner, James D.
    [J]. VACCINE, 2010, 28 (33) : 5485 - 5490
  • [3] COST-EFFECTIVENESS OF INFANT VACCINATION WITH 10 AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE RUSSIAN FEDERATION
    Rudakova, A., V
    Sidorenko, S.
    Kharit, S. M.
    Uskov, A.
    Lobzin, Y., V
    Shchurov, D. G.
    Topachevskyi, O.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A525 - A525
  • [4] A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A428 - A428
  • [5] Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
    Stephanie R Earnshaw
    Cheryl L McDade
    Giovanni Zanotti
    Raymond A Farkouh
    David Strutton
    [J]. BMC Infectious Diseases, 12
  • [6] COST-UTILITY ANALYSIS OF 10-AND 13-VALENT PNEUMOCOCOCCAL CONJUGATE VACCINES IN THE PHILIPPINES
    Haasis, M. A.
    Ceria, J. A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A807 - A807
  • [7] Cost-effectiveness of 2+1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
    Earnshaw, Stephanie R.
    McDade, Cheryl L.
    Zanotti, Giovanni
    Farkouh, Raymond A.
    Strutton, David
    [J]. BMC INFECTIOUS DISEASES, 2012, 12
  • [8] COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)
    Rozenbaum, M.
    Sanders, E. A.
    van Hoek, A.
    Jansen, A. G.
    van de Ende, A.
    Rodenburg, G.
    van den Dobbelsteen, G.
    Hak, E.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A294 - A294
  • [9] Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
    Sundaram, Neisha
    Chen, Cynthia
    Yoong, Joanne
    Luvsan, Munkh-Erdene
    Fox, Kimberley
    Sarankhuu, Amarzaya
    La Vincente, Sophie
    Jit, Mark
    [J]. VACCINE, 2017, 35 (07) : 1055 - 1063
  • [10] COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN KAZAKHSTAN
    Bektur, C.
    Nurgozhin, T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A106 - A106